Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.

@article{GombergMaitland2006AnticoagulationIW,
  title={Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials.},
  author={Mardi Gomberg-Maitland and Nanette K Wenger and Jan M Feyzi and M{\'a}ria Lengyel and Annabelle Santos Volgman and Palle Petersen and Lars Frison and Jonathan L. Halperin},
  journal={European heart journal},
  year={2006},
  volume={27 16},
  pages={1947-53}
}
AIMS The risk of stroke is greater among women with atrial fibrillation (AF) than men. Warfarin protects against stroke, but treatment-related bleeding occurs more often in women than in men. METHODS AND RESULTS SPORTIF III (open label, n=3410) and V (double-blind, n=3922) included 2257 women with AF and one or more stroke risk factors randomized to warfarin [target international normalized ratio (INR) 2.0-3.0] or ximelagatran (36 mg twice daily). Primary outcomes were all stroke (ischaemic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 35 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 23 references

ACTIVE W. Presented at American Heart Association Meeting, Dallas

  • SJ Connolly
  • 2005
1 Excerpt

Committee; SPORTIF V Investigators

  • SPORTIF Executive Steerin
  • Ximelagatran vs. warfarin for stroke prevention…
  • 2005

Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women vs men (The Copenhagen City Heart Study)

  • J Friberg, H Scharling, N Gadsboll, T Truelsen, GB. Jensen
  • Am J Cardiol 2004;94:889–894
  • 2004

Similar Papers

Loading similar papers…